



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete If Known**

Application Number	09/995,225
Filing Date	November 26, 2001
First Named Inventor	Ruoping Chen et al.
Art Unit	1646
Examiner Name	Nirmal Singh Basl
Attorney Docket Number	21.US18.CIP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CO	ELBLE, RODGER, J., "Animal Models of Action Tremor," <i>Movement Disorders</i> , 13(3):35-39, (1998)	
	CP	JELJELI, M., ET AL., "Effects of centrolateral or medial thalamic lesions on motor coordination and spatial orientation in rats," <i>Neuroscience Research</i> , 38:155-164, (2000)	
	CQ	KARPE, F. and FRAYN, K.N., "The nicotinic acid receptor—a new mechanism for an old drug," <i>The Lancet</i> , 363:1892-1894, (June, 2004)	
	CR	McNAMARA, J.O. "Drugs Effective in the Therapy of the Epilepsies," <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i> , Ninth Edition, Chapter 20, pp. 461-486	
	CS	PORTAS, C.M., ET AL., "A Specific Role for the Thalamus in Mediating the Interaction of Attention and Arousal in Humans," <i>The Journal of Neuroscience</i> , 18(21):8979-8989, (November, 1998)	
	CT	PROBST, WILLIAM C., ET AL., "Sequence Alignment of the G-Protein Coupled Receptor Superfamily," <i>DNA and Cell Biology</i> , 11(1):1-20, (1992)	
	CU	SONNHAMMER, ERIK L.L., ET AL., "A Hidden Markov Model for Predicting Transmembrane Helices in Protein Sequences," <i>Proc. Int. Conf. Intell. Syst. Mol. Biol.</i> , 6:175-82, (1998)	
	CV	ZADINA, J.E., ET AL., "Endomorphins: Novel Endogenous $\mu$ -Opiate Receptor Agonists in Regions of High $\mu$ -Opiate Receptor Density," <i>Annals New York Academy of Sciences</i> , 897:136-144, (1999)	

Examiner Signature	Nirmal Sr	Date Considered	7/24/05
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\*\*A COPY OF THIS REFERENCE WILL NOT BE FORWARDED TO THE U.S. PATENT AND TRADEMARK OFFICE SINCE IT IS BELIEVED TO BE TOO VOLUMINOUS AND EASILY OBTAINABLE BY THE EXAMINER.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.